- ICB-treated survivors had poorer objective neurocognitive performance than matched controls, especially learning and memory; impairment decreased over time from 49% to 27%.
- Subjective cognitive complaints affected 20%, were stable, and associated with anxiety, depression, fatigue, PTSD, and fear of recurrence, but not with objective NCF.
- Fear of cancer recurrence affected 53% of survivors, 22% pathological, persisting over time; psychological symptoms remained prevalent, supporting routine screening and timely interventions.
Cancer. 2026 Dec 1;132(23):e70668. doi: 10.1002/cncr.70668.
ABSTRACT
BACKGROUND: Immune checkpoint blockade (ICB) has led to a growing population of long-term advanced cancer survivors. However, data on neurocognitive functioning (NCF) and psychological outcomes after ICB remain limited, particularly from longitudinal studies incorporating control groups.
METHODS: In this prospective longitudinal study, cancer survivors who had ICB-treated, unresectable, stage III-IV disease completed neuropsychological testing and patient-reported outcome measures (PROMs) at baseline and at 6-month and 18-month follow-up. Objective NCF was compared with healthy matched controls. Linear mixed models evaluated longitudinal changes, and correlation analyses examined associations between NCF and PROMs.
RESULTS: Of the 112 eligible patients, 79 were included. The median time since ICB initiation was 5.3 years. Compared with matched controls, survivors demonstrated poorer performance in learning and long-term memory. Objective neurocognitive test performance improved over time, with the prevalence of neurocognitive impairment decreasing from 49% to 27%. Subjective cognitive complaints affected 20% of survivors, remained stable, and were strongly associated with anxiety, depressive symptoms, fatigue, post-traumatic stress disorder, fear of cancer recurrence, and poorer quality of life, but not with objective NCF. Significant fear of cancer recurrence affected 53% of survivors, including 22% with pathologic levels, and persisted over time. Fatigue, anxiety, depressive symptoms, and post-traumatic stress disorder symptoms were also prevalent and stable throughout follow-up.
CONCLUSIONS: Survivors who received treatment with ICB demonstrated poorer neurocognitive test performance than healthy matched controls, particularly in learning and memory, but showed gradual improvement over time. In contrast, psychological symptoms, especially fear of cancer recurrence, persisted. These findings support routine survivorship screening, timely referral to interventions for fear of cancer recurrence, and integrative management of cognitive and psychological symptoms.
PMID:43046925 | DOI:10.1002/cncr.70668
Share Evidence Blueprint
Save to Google Notes

Search Google Scholar
⭐ My Revision List

